Obeldesivir Placebo

DRUG4 trials

Sponsors

Gilead Sciences

Conditions

COVID-19RSV Infection

Phase 2

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

TerminatedNCT06585150

Gilead SciencesRSV Infection

Start: 2024-10-14End: 2025-06-09Updated: 2026-06-30

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

TerminatedNCT06784973

Gilead SciencesRSV Infection

Start: 2025-03-05End: 2025-04-16Updated: 2026-06-08

Phase 3

Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

TerminatedNCT05603143

Gilead SciencesCOVID-19

Start: 2022-11-05End: 2023-11-07Updated: 2024-12-20

Study of Obeldesivir in Nonhospitalized Participants With COVID-19

CompletedNCT05715528

Gilead SciencesCOVID-19

Start: 2023-02-08End: 2024-01-23Updated: 2024-12-24

Related Papers

SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19.

2026-01-19

SARS-CoV-2 Resistance Analyses From the Phase 3 OAKTREE Study of Obeldesivir in Low-Risk Nonhospitalized Participants With COVID-19.

2025-12-29

Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With Coronavirus Disease 2019 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Clinical Infectious Diseases2025-07-223 citations

Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.

2025-07-142 citations